SPONTANEOUS PATHOLOGICAL COMPLETE REGRESSION OF HIGH-GRADE TRIPLE-NEGATIVE BREAST CANCER WITH AXILLARY METASTASIS

被引:0
作者
Cserni, Gabor [1 ]
Serfozo, Orsolya [2 ]
Ambrozay, Eva [2 ]
Marko, Laszlo [3 ,4 ]
Krenacs, Laszlo [5 ]
机构
[1] Univ Szeged, Inst Pathol, Allomas U 1, H-6720 Szeged, Hungary
[2] Mamma Rt, Breast Imaging Unit, Kecskemet, Hungary
[3] Bacs Kiskun Cty Teaching Hosp, Dept Oncol, Kecskemet, Hungary
[4] Bacs Kiskun Cty Teaching Hosp, Dept Surg, Kecskemet, Hungary
[5] Lab Tumour Pathol & Mol Diagnost, Szeged, Hungary
关键词
PD-L1; spontaneous regression; tumour-infiltrating lymphocytes; triple-negative breast cancer; LIGAND; 1; EXPRESSION; CARCINOMA; PROGNOSIS;
D O I
10.5114/PJP.2019.87105
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We report on a breast carcinoma with medullary features diagnosed by core needle biopsy in a 72-year-old woman. Both the primary tumour and its fine needle aspiration-proven, rapidly growing axillary metastasis regressed completely in less than 2 months, by the time surgery was performed. The biopsy of the primary tumour demonstrated a dense stromal infiltrate of CD8+/granzyme B+ activated cytotoxic T-cells suggestive of a robust antitumour immune response. Paradoxically, both tumour cells and tumour infiltrating immune cells demonstrated a diffuse PD-L1 expression, revealing that antitumour immune response has the ability to spontaneously overcome inhibitory mechanisms induced by cancerous growth.
引用
收藏
页码:139 / 143
页数:5
相关论文
共 50 条
  • [31] The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
    Michaels, Elena
    Chen, Nan
    Nanda, Rita
    CLINICAL BREAST CANCER, 2024, 24 (04) : 263 - 270
  • [32] Prognostic values of EDNRB in triple-negative breast cancer
    Liu, Shaoqing
    Zhang, Jingyang
    Zhu, Jiujun
    Jiao, Dechuang
    Liu, Zhenzhen
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [33] Progress and challenges of immunotherapy in triple-negative breast cancer
    Zhu, Yinxing
    Zhu, Xuedan
    Tang, Cuiju
    Guan, Xiaoxiang
    Zhang, Wenwen
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [34] Dysfunctional mismatch repair in patients with early triple-negative breast cancer
    Muniz-Castrillo, Maria
    Boluda, Noel Blaya
    Garcia-Torralba, Esmeralda
    Jimenez-Fonseca, Paula
    del Rey, Carmen Gonzalez
    Balbin, Milagros
    Luengo-Gil, Gines
    de la Pena, Francisco Ayala
    Gonzalez, Emilio Esteban
    Carmona-Bayonas, Alberto
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [35] Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer
    Ceprnja, Toni
    Mrklic, Ivana
    Peric Balja, Melita
    Marusic, Zlatko
    Blazicevic, Valerija
    Spagnoli, Giulio Cesare
    Juretic, Antonio
    Capkun, Vesna
    Tecic Vuger, Ana
    Vrdoljak, Eduard
    Tomic, Snjezana
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (06):
  • [36] Targeting the androgen receptor in triple-negative breast cancer
    Gucalp, Ayca
    Traina, Tiffany A.
    CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 141 - 150
  • [37] The clinical promise of immunotherapy in triple-negative breast cancer
    Vikas, Praveen
    Borcherding, Nicholas
    Zhang, Weizhou
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6823 - 6833
  • [38] ETS1 is a prognostic biomarker of triple-negative breast cancer and promotes the triple-negative breast cancer progression through the YAP signaling
    Li, Yanlin
    Wu, Tiantian
    Peng, Ziluo
    Tian, Xianyan
    Dai, Qian
    Chen, Miao
    Zhu, Jun
    Xia, Song
    Sun, Aiqin
    Yang, Wannian
    Lin, Qiong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (11): : 5074 - 5084
  • [39] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [40] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620